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Abstract
A series of carbamides derived from 1,2:5,6-di-O-isopropylidene-D-gluco- (1) and  D-allofuranose 
(3) as well as their 5,6-O-deprotected analogues (2 and 4) and methyl 3,4-O-isopropylidene-α- and 
β-D-galactopyranosides (5 and  6) have been prepared in order to evaluate their ability to induce 
erythroid differentiation of human erythroleukemic K562 cells. Twenty out of the 51 carbamides 
tested exhibit an appreciable activity as inducers of erythroid differentiation and have been fully 
characterised and described.
1. Introduction
The K562 cell line, isolated and characterized by Lozzio and Lozzio1 from a patient with chronic 
myelogenous  leukemia  in  blast  crisis,  has  been  proposed as  a  very useful  experimental  model 
system to identify inducers of γ-globin gene expression of possible interest in the therapy of several 
haematological diseases, including β-thalassemia and sickle cell anaemia.2 
K562 cells exhibit a low proportion of hemoglobin-synthetizing cells under standard cell growth 
conditions,  but  are  able  to  undergo  erythroid  differentiation  when  treated  with  a  variety  of 
compounds,  including short  fatty acids, 5-azacytidine,  mithramycin,  and chromomycin,  cisplatin 
and cisplatin analogues, tallimustine, rapamycin, everolimus, psoralens and resveratrol.3 Following 
erythroid induction, a sharp increase of expression of human  ε and  γ globin genes is observed in 
K562 cells, leading to a cytoplasmic accumulation of Hb Portland (ζ2γ2) and Hb Gower 1 (ζ2ε2), .4-7 
Among possible biological response modifiers,  one of the most studied classes of compound  is 
represented by short fatty acids,  especially butyric  and pivalic acids and related esters. Glycide 
 Authors for correspondence. G.C.: phone +39 050 2219678, fax +39 050 2219660, e-mail giocate@farm.unipi.it; 
R.G: phone +39 0532 424443, fax +39 0532 202723, e-mail gam@unife.it
1
esters have been initially proposed merely as convenient prodrugs, able to gradually release the 
pharmacophore following the in vivo action of esterases.8 
In  recent  papers  regarding  the  synthesis  and  evaluation  of  some  partially  acetonated 
monosaccharide esters of several fatty acids we have highlighted the role of the structure of either 
the ester and the carbohydrate residue in the antiproliferative effects and erythroid differentiation 
activity of K562 cells.9 Furthermore, it was observed that some glycose isobutyrates and pivaloates 
stimulate  erythroid  differentiation  to  higher  levels  than  the  corresponding  free  fatty  acids.9 
Consequently, we assumed that, at least in the case of isobutyrates and pivaloates, the biological 
activity of monosaccharide esters might be related to the whole structure prior to the occurrence of 
the hydrolysis takes place, rather than to the release of the free fatty acid acting as biologically 
active component.
Unfortunately, fast in vivo ester hydrolysis  on rabbit10 precludes the possibility of any therapeutic 
use of glycide esters. Therefore, we turned our efforts to investigate some more stable isosters of 
active glycose esters. Among various possibilities, we decided to focus on the substitution of the 
ester group with an amide one, which would offer the advantage of a simple synthetic access. 
The present paper deals  with the synthesis  and the biological evaluation of part of a library of 
glycose carbamides 1-6  (chart  1) in which the carbohydrate scaffoldings where the same of the 
previously described biologically active glycide esters.9 Besides butyrates and pivaloates, we have 
selected a wide set of acyl residues classified into three groups (Chart 1): the first one includes 
linear and branched fatty acids (group A), the second one contains residues characterized by the 
presence of aromatic or heteroaromatic rings (group B) and the third one is a miscellaneous group 
(group C) including residues with heteroatoms or unsaturations within the chain. 
A subset of 51 compounds, out of 174 glycose carbamides represented in Chart 1, were synthesised 
and tested towards  for biological activity on the K562 cellular system a subset, 20 of them showed 
an appreciable erythroid differentiation inducing activity on K562 cells. Synthesis, characterization 
and ability to induce erythroid differentiation of these biologically active compounds are herein 
presented.
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a: R = CH2-C6H5, b: R = CH2-(3-OMe)C6H4, c: R = CH2-(4-OMe)C6H4,
d: R = CH2-(2,5-di-OMe)C6H3,e: R = CH(C6H5)2, f: R = CH2CH2-C6H5,
g: R = C6H5, h: R = (4-C6H5)-C6H4, i: R = (4-OMe)C6H4, j: R = C6H4N
GROUP A
a: R = CH3, b: R = CH2CH3, c: R = (CH2)2CH3, d: R = (CH2)3CH3,
e: R = (CH2)4CH3, f: R = CH2CH(CH3)2,g: R = CH2CH(CH3)CH2C(CH3)3,
h: R = CH2C(CH3)3,i: R = CH(CH3)2, j: R = C(CH3)3,
k: R = CH2CH2(CH2)5, l: R = (CH2)3, m: R = (CH2)4,
n: R = (CH2)5, o: R = (CH2)6
GROUP B
GROUP C
Chart 1
2. Chemistry
3-Amino-3-deoxy-1,2:5,6-di-O-isopropylidene-α-D-hexofuranose scaffolds  711 and  812 (Scheme 1) 
were prepared according to literature  procedures.  The synthesis  of methyl  α- and  β-6-amino-6-
deoxy-3,4-O-isopropylidene-D-galactopyranosides 15 and 16 was easily achieved starting from the 
corresponding anomeric diols  913 and  1013 and employing the same reaction sequence. Reaction 
ofboth 9 and 10 with a slight excess of p-toluenesulphonyl choride caused the expected selective14,15 
tosylation  of  primary  OH  group.  The  resulting  6-sulphonates  were  subjected  to  nucleophilic 
3
displacement  with  NaN3,  followed  by  reduction  of  resulting  azides  to  furnish  15 and  16 in 
satisfactory overall yield (39 and 45%, respectively).
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Conditions: i) TsCl, Py. ii) NaN3, DMF. iii) LiAlH4, Et2O
11: R= H, R'=OMe
12: R=OMe, R'=H
13: R= H, R'=OMe
14: R=OMe, R'=H
15: R= H, R'=OMe
16: R=OMe, R'=H
Scheme 1
The glycose carbamide of type 1, 3, 5 and 6 were prepared through parallel synthesis by treatment 
of the four aminated scaffolds 7,  8,  15 and 16 with an excess of the appropriate commercial acyl 
chlorides in methylene chloride in the presence of PS-piperidinomethyl resin (Scheme 2). 
Partially protected furanosic carbamides of type 2 and 4 (scheme 1) were obtained from protected 
ones (1 and  3)  through selective  hydrolytic  removal  of 5,6 acetonide  group with 80% aqueous 
AcOH.  In  the  case  of  the  D-allose  series  (3)  acid  hydrolysis  was  conducted  under  milder 
temperature conditions (45 °C) with respect to that used for D-glucose analogues (60 °C), in order to 
prevent  complete  removal  of  the  two  acetal  groups.  As  pointed  out  by  Collins,16 in  fact,  the 
hydrolysis rate of the 1,2-O-isopropylidene functionality in the D-allose series is higher with respect 
to that observed for analogous acetonide functionality in the D-glucose series.16 All the compounds 
were  fully  characterized  by  1H-  and  13C-NMR  and  standard  analytical  parameters  (see  the 
Experimental section).
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3. Biological activity
The human leukemia K562 cell line17 was kept in a humidified atmosphere of 5% CO2/air in RPMI 
1640 medium (Sigma, St. Louis,  MO, USA) supplemented with 10% fetal  bovine serum (FBS; 
celbio, MI, Italy), 50 Units/mL penicillin and 50 µg/mL streptomycin.18 In order to determine the 
ability of the tested compounds to inhibit the cell growth and induce the erythroid differentiation, 
K562 cells (30,000 cells/mL) were cultured both in the absence and in the presence of the indicated 
concentrations  of  compounds  and  the  cell  number/mL  determined  with  a  ZF  Coulter  Counter 
(Counter Electronics, Hialeah, FL, USA) at different days from the culture set-up. In order to verify 
possible effects on erythroid differentiation, the proportion of benzidine-positive K562 cells was 
determined and compared  to  the values  obtained employing  other  known inducers  of erythroid 
differentiation,  including  cytosine  arabinoside  (ara-C),19  mithramycin,3 rapamycin3 and  butyric 
acid.3
Among the tested carbamides (1Ca, 1Ac, 1Al, 2Aa, 2Ab, 2Ac, 2Ad, 2Ae, 2Af, 2Ag, 2Ah, 2Ai, 
2Aj, 2Ak, 2Am, 2An, 2Ao, 2Be, 2Ca, 2Cb, 3Ab, 3Ad, 3Af, 3Ah, 3Al, 3An, 3Ba, 3Bb, 3Bc, 3Bd, 
Table  1.  Effects  of  active  carbamides  on  in  vitro 
growth  and  erythroid  differentiation  of  human 
leukemic K562 cells
Compound IC50 value(mM) Erythroid inductiona 
(% of benzidine-
positive cells)
1Ca 0.5 mM 19 ± 3.5
2Ab 30.0 mM 20 ± 4.4
2Ac 0.5 mM 20 ± 4.5
2Ad 5.0 mM 18 ± 3.2
2Ae 10.0 mM 28 ± 6.5
2Af 5.0 mM 25 ± 5.2
2Ah 5.0 mM 15 ± 3.3
3Ab 7.5 mM 19 ± 4.5
3An 1.0 mM 21 ± 3.2
4Ac 20.0 mM 20 ± 3.7
4Aj 20.0 mM 25 ± 7.2
4Bi 2.5 mM 24 ± 4.7
5Ac 0.1 mM 18 ± 4.4
6Al 0.25 mM 27 ± 5.5
Ara-C 500 nM 78. ± 2 4.5
mithramycin 100 nM 86. ± 4 8.3
rapamycin 1.0 mM 75.5 ± 7.5
butyric acid 2.0 mM 32.5 ± 3.4
aResults  are  presented  as  average  ±  SD  (three  independent 
experiments  performed)  of  %  of  benzidine-positive 
(haemoglobin-containing) cells after 6 days induction period at 
the indicated concentrations of the tested compounds.
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3Bf, 3Bg, 3Bi, 3Bj, 3Ca, 4Ac, 4Ac, 4Ai, 4Aj, 4Al, 4An, 4Bb, 4Bg, 4Bh, 4Bi, 4Bj, 4Cc, 4Cd, 5Ac, 
6Al, 6Ac) fourteen (1Ca, 2Ab, 2Ac, 2Ad, 2Ae, 2Af, 2Ah, 3Ab, 3An, 4Ac, 4Aj, 4Bi, 5Ac, 6Al) 
were found to exhibit appreciable (≥ 15%) erythroid differentiation effect, while nine (2Ac, 2Aj, 
3Bb, 3Bf, 3Bd, 4Ac, 4Ai, 4Bh, 4Aj), three of which (2Ac, 4Ac and 4Aj) active on their own, were 
the compounds resulted active in synergism, potentiating erythroid induction of K562 cells treated 
with sub-optimal concentrations of ara-C. The data obtained on erythroid differentiation are shown 
into Tables 1 and 2.
Table 2. Synergism between ara-C and carbamides on in  
vitro growth and erythroid differentiation of human 
leukemic K562 cells
Compound Concentration 
(mM)
Erythroid inductiona (% of 
benzidine-positive cells)
2Ac 0,5 mM 35 ± 3.8 %
2Aj 5.0 mM 68 ± 5.5
3Bf 0.75 mM 49 ± 6.1
3Bb 1.0 mM 43 ± 4.4
3Bd 0,5 mM 50 ± 4.3
4Ac 20 mM 40 ± 3.5
4Ai 8.0 mM 66 ± 7.8
4Aj 20 mM 40 ± 5.6
4Bh 0.1 mM 33 ± 4.4
Ara-C 500 nM 22 ± 2.8
aResults are presented as average ± SD (three independent experiments 
performed) of % of benzidine-positive (haemoglobin-containing) cells 
after  6 days  induction period at  the indicated concentrations  of  the 
tested  compounds.  Sub-optimal  concentrations  of  ara-C  (200  nm) 
were used in combination with the tested compounds.
When  the  analysis  of  the  structure  of  carbamides  active  in  the  stimulation  of  erythroid 
differentiation was performed, it was found that seven of those exhibited linear saturated fatty acid 
residues,  three  branched  saturated  fatty  acid  residues  and two alicyclic  residues.  However,  we 
underline that many amides of linear, branched and most of alicyclic fatty acid residue are present 
in the list of inactive tested amide (i.e.  2Ak,  3Af,  5Ac,  2An).  In addition, it should be note that, 
despite the well known activity of phenylbutyrates and phenylacetates,20 only one of the fourteen 
aromatic  rings  containing  the  tested  amides  exhibits  activity.  In  contrast,  among  the  nine 
carbamides active in synergism with ara-C, four bear aromatic rings. 
With  respect  to  the  role  of  sugar  scaffold,  we  did  not  recognise  any  clear  structure-activity 
relationship  either  related  to  the  protection/deprotection  of  glycide  [compare  couples  1Ac 
(inactive)/2Ad (active) and 1Ca (active)/2Ca (inactive)] or to the stereochemistry of carbon bearing 
the  pharmacophore  [compare  couples  2Ac (active)/4Ac (active),  2Ai (inactive)/4Ai (active  in 
synergism) and 2Aj (active in synergism)/4Aj (active)]. 
6
In conclusion, the majority of active glycose carbamides act with a mechanism resembling ara-C 
(no synergism observed with ara-C); three carbamides (2Ac, 4Ac and 4Aj) display a mechanism of 
action presumably different compared to that exhibited by sub-optimal concentrations of ara-C; six 
(2Aj,  3Bf,  3Bb,  3Bd,  4Ai and  4Bh),  which are not active  by themselves,  are however  able to 
enhance  ara-C  mediated  erythroid  induction.  Whether  they  induce  a  part  of  the  erythroid 
differentiation program complementary to that stimulated by sub-optimal concentrations of ara-C 
remains to be investigated.
As far as structure-activity relationship (SAR) analysis, we like to underline that compounds of type 
2 display the highest probability (35% in our set) to induce differentiation (6/17, compared to 2/15 
and 3/13 of compounds of type  3 and  4, respectively). Compounds carrying residues of group  A 
display the highest probability (36%) to induce erythroid differentiation (11/31, compared to 1/14 
and 1/6 of compounds carrying residues of group B and C, respectively).
More in detail,  all the compounds carrying the residue  Ab (R = CH2CH3) and three out of five 
compounds carrying residue Ac [R = (CH2)2CH3] were found able to induce differentiation (two of 
them, 2Ac and 4Ac, also in synergism with ara-C). With respect to synergism with ara-C, only the 
compounds  carrying the residue R = C(CH3)3 (2Aj and  4Aj)were found to be active in inducing 
high level of differentiation.
Despite being limited, this SAR analysis suggest that the most promising molecules able to induce 
differentiation are glycose carbamides of type 2 or those displaying residues Ab (R = CH2CH3) and 
Ac [R = (CH2)2CH3]. Residue  Aj [R = C(CH3)3] appears to be involved in the property to act in 
synergism with ara-C. Obviously, this hypothesis is not conclusive, due to our choice of a diversity 
oriented selection of compounds within the complete library of carbamides. This choice has allowed 
to explore some representative of each class of acyl residue, but it has prevented the performance of 
a systematic sight on the effect of glycide scaffold in biological activity when a same acyl residue is 
considered.  The  SAR analysis  here  discussed should be  considered  a  starting  point  for  further 
synthetic activity toward the generation of other oriented set of analogues, thus helping to verify 
this hypothesis.
4. Experimental section
4.1. General methods
Melting points  were determined with a Kofler hot-stage apparatus  and are  uncorrected.  Optical 
rotations were measured on a Perkin–Elmer 241 polarimeter at 20 ± 2 °C.  1H NMR spectra were 
recorder in appropriate solvents (internal standard Me4Si) with a Bruker AC 200 instrument at 200 
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MHz and with a Bruker AvanceII operating at 250 MHz. 13C NMR spectra were recorder with the 
spectrometers  operating  at  50 and 62.9  MHz.  Assignments  were  made  with  the  aid  of  DEPT, 
HETCOR and  COSY experiments  and  by  comparison  with  values  for  known compounds  and 
applying the known additivity rules.21 All reactions were followed by TLC on Kieselgel 60 F254 (E. 
Merck) with detection by UV light and/or with ethanolic 10% phosphomolybdic or sulphuric acid, 
and heating. Kieselgel 60 (E. Merck, 70-230 and 230-400 mesh, respectively) was used for column 
and  flash  chromatography.  Parallel  reactions  were  followed  by  HPLC-MS  analyses  (Waters 
Acquity  UPLC,  with  Waters  Acquity  PAD  detector  and  Micromass  ZQ  2000  mass  analyzer, 
controlled by PC with MassLynx TM 4.1, column Waters Acquity UPLC BEH C18 2.1 x 50 mm, 
1.7  micron,  eluent:  H2O/CH3CN/HCOOH  95/5/0,05  v/v/v).  Solvents  were  dried  by  distillation 
according to standard procedures,22 and storage over 4Å molecular sieves activated for at least 24 h 
at 250 °C. MgSO4 was used as the drying agent for solutions. Acyl chlorides were purchased from 
Aldrich, with the exception of cyclopropanecarbonyl  chloride prepared from corresponding acid 
according to literature procedure.23 PS-piperidinomethyl resin and polyamine resin were purchased 
from Novabiochem. 
4.2. Amino scaffolds
3-Ammino-3-deoxy-1,2:5,6-di-O-isopropylidene-α-D-glucofuranose11 (7)  and  3-ammino-3-
deoxy-1,2:5,6-di-O-isopropylidene-α-D-allofuranose12 (8) were synthesized as reported.
4.2.1. Methyl-3,4-O-isopropylidene-6-O-methylsulphonyl-α-D-galactopyranoside (11)
A solution of 913 (1.00 g, 4.27 mmol) in pyridine (25 mL) was treated at 0 °C under stirring with 
commercial methylsulphoyl chloride (896 mg, 4.70 mmol). The solution was allowed to warm to 
room temperature and stirred until the TLC analysis (EtOAc) showed the complete disappearance 
of the starting material (74 h) and the formation of one component (Rf 0.51). The reaction mixture 
was repeatedly coevaporated   with toluene  (5 × 15 mL)  under  diminished pressure.  The crude 
residue was partitioned between CH2Cl2 (60 mL) and H2O (30 mL), the aqueous phase extracted 
with CH2Cl2 (4 × 40 mL) and the organic ones were collected, dried (MgSO4) and concentrated 
under diminished pressure. Flash chromatography on silica gel (petroleum ether-EtOAc 2:1) of the 
crude solid led to pure 15 (1.07 g, 64%) as a white solid. Rf 0.51 (EtOAc); mp (EtOAc) 127-129 °C; 
lit24 129 °C. 1H NMR (CDCl3, 200 MHz): δ 7.82 (AA’XX’, 2H, Ar-H), 7.35 (AA’XX’, 2H, Ar-H), 
4.70 (d, 1H, J = 3.9 Hz, H-1), 4.28-4.12 (m, 5H, H-6a, H-6b, H-2, H-3, H-4), 3.79 (m, 1H, H-5), 
3.41 (s, 3H, OMe, 2.45 (s, 3H, MePh), 1.42, 1.29 (2s, each 3H, CMe2). 13C NMR (CDCl3, 50 MHz): 
δ 133.2, 144.8 (2 x Ar-C), 128.0, 129.8 (4 x Ar-CH), 110.0 (CMe2), 97.8 (C-1), 75.6 (C-3), 72.4 
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(C-4), 68.7, 69.2 (C-2, C-5), 66.5 (C-6), 55.5 (OMe), 25.7, 27.4 (CMe2), 21.6 (MePh). Compound 
11 was stored at 4 °C or lower temperature to prevent degradation.
4.2.2. Methyl-3,4-O-isopropylidene-6-O-methylsulphonyl-β-D-galactopyranoside (12)
This compound was prepared starting from 1013 (3.10 g, 13.3 mmol) by a procedure analogous to 
that of 11. White solid, 3.61 g (70%). Rf 0.57 (EtOAc); mp (EtOAc) 157-159 °C; lit15 154-155 °C; 
optical rotation (c +1.0, CHCl3): [α]D +1.0; lit15 (c 2.3, CHCl3): [α]D 1.0.  1H NMR (CDCl3, 200 
MHz):  δ 7.81 (AA’XX’, 2H, Ar-H), 7.35 (AA’XX’, 2H, Ar-H), 4.28 (d, 1H,  J1,2 =8.2 Hz, H-1), 
4.23, 4.07 (2m, 5H, H-3, H-4, H-5, H-6a, H-6b), 3.47 (dd, 1H,  J2,3 = 6.5 Hz, H-2), 3.47 (s, 3H, 
OMe), 2.46 (s, 3H, MePh), 1.44, 1.29 (2s, each 3H, CMe2).  13C NMR (CDCl3, 50 MHz): δ 145.1, 
132.1 (2 x Ar-C), 127.9, 128.9 (4 x Ar-CH), 110.5 (CMe2), 103.0 (C-1), 78.5 (C-3), 73.4, 72.9, 71.0 
(C-2, C-4, C-5), 68.6 (C-6), 57.0 (OMe), 27.9, 26.2 (Me2C), 21.6 (MePh). Compound 12 has to be 
stored at 4 °C or lower temperature to prevent degradation.
4.2.3. Methyl-6-azido-6-deoxy-3,4-O-isopropylidene-α-D-galactopyranoside (13)
A solution of  11 (1.00 g, 2.58 mmol) in DMF and (35 mL) was treated with commercial sodium 
azide (355 mg,  5.15 mmol).  The suspension was warmed to  120 °C and stirred until  the TLC 
analysis (petroleum ether-EtOAc 1:1) showed the complete disappearance of the starting material 
(28 h) and the formation of one component (Rf 0.35). The reaction mixture was allowed to cool to 
room temperature and concentrated under diminished pressure. The crude residue was partitioned 
between CH2Cl2 (35 mL) and H2O (30 mL), the aqueous phase extracted with CH2Cl2 (5 × 25 mL) 
and the organic ones were collected, dried (MgSO4) and concentrated under diminished pressure. 
Flash chromatography on silica gel (petroleum ether-EtOAc 1:1) of the crude syrup led to pure 13 
(677 mg, 77%) as a syrup. Rf 0.35 (petroleum ether-EtOAc 1:1); optical rotation (c 1.2, CHCl3) [α]D 
+89.4. 1H NMR (CDCl3, 200 MHz): δ 4.78 (d, 1H, J1,2 = 3.9 Hz, H-1), 4.29 (t, 1H, J2,3 = J3,4= 6.1 
Hz, H-3), 4.14 (m, 2H, H-5, H-4), 3.85 (m, 1H, H-2), 3.59 (dd, 1H, J5.6b = 8.3 Hz, H-6b), 3.50 (s, 
3H, OMe), 3.33 (dd, 1H, J6a,6b = 12.9 Hz, J5,6a = 4.3 Hz, H-6a), 2.53 (d, 1H, J2,OH =5.7 Hz, OH), 1.51, 
1.35 (2s, each 3H, CMe2). 13C NMR (CDCl3, 50 MHz): δ 109.9 (CMe2), 98.1 (C-1), 75.6 (C-3), 73.1 
(C-4), 68.8, 67.9 (C-5, C-2), 55.6 (OMe), 51.2 (C-6), 27.4, 25.7 (CMe2). Anal. for C10H17N3O5. Calc. 
(%): C, 46.33; H, 6.61; N, 16.21. Found (%): C, 44.66; H, 6.47; N, 15.66.
4.2.4. Methyl-6-azido-6-deoxy-3,4-O-isopropylidene-β-D-galactopyranoside (14)
This compound was prepared starting from 12 (1.50 g, 3.87 mmol) by a procedure analogous to that 
of 13. White solid, 792 mg (79%). Rf 0.22 (petroleum ether- EtOAc 1:1); mp (hexane) 80-82 °C; 
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optical rotation (c 1.0, CHCl3): [α]D -16.6. 1H NMR (CDCl3, 200 MHz): δ 4.14 (d, 1H, J1,2 = 8.0 Hz, 
H-1), 4.10 (m, 2H, H-3, H-4), 3.94 (ddd, 1H, J4.5 = 1.7 Hz, H-5), 3.73 (dd, 1H, J5,6b = 8.3 Hz, H-6b), 
3.57 (s, 3H, OMe), 3.54 (m, 1H, H-2), 3.33 (dd, 1H, J6a,6b = 12.9 Hz, J5,6a = 4.2 Hz, H-6a), 2.85 (bs, 
1H, OH), 1.35, 1.53 (2s, each 3H, CMe2). 13C NMR (CDCl3, 50 MHz): δ 110.4 (CMe2), 103.1 (C-1), 
78.6 (C-3), 73.5, 73.7, 72.9 (C-2, C-5, C-4), 57.0 (OMe), 51.0 (C-6), 26.2, 27.9 (CMe2). Anal. for 
C10H17N3O5. Calc. (%): C, 46.33; H, 6.61; N, 16.21. Found (%): C, 44.28; H, 6.32; N, 16.32.
4.2.5. Methyl-6-amino-6-deoxy-3,4-O-isopropylidene-α-D-galactopyranoside (15)
To a suspension of LiAlH4 (93 mg, 2.5 mmol) in dry Et2O (10 mL) at 0 °C a solution of 13 (260 
mg, 1.0 mmol) in dry Et2O (6 mL) was added drop wise and under stirring. The suspension was 
warmed  to  reflux  and stirred  until  the  TLC analysis  (petroleum ether-EtOAc 1:1)  showed the 
complete disappearance of the starting material (30 min) and the formation of one component (Rf 
0). The reaction mixture was cooled to 0 °C, diluted with Et2O and treated in sequence with 1 mL of 
water,  2  mL of  10% aqueous  NaOH and  3  mL of  water,  obtaining  the  formation  of  a  white 
precipitate. The mixture was filtered, the solid washed with CH2Cl2 (4 × 5 mL) and the organic ones 
were collected,  dried (MgSO4) and concentrated under diminished pressure to provide crude  15 
(184 mg, 79%). Crystallization (EtOAc) of the crude solid furnished 15 as a white crystalline solid. 
mp 152-157 °C; optical rotation (c 1.0, CHCl3): [α]D +145.7. 1H NMR (CDCl3, 200 MHz): δ 4.76 
(d, 1H, J1,2 = 3.8 Hz, H-1), 4.21 (m, 2H, H-4, H-5), 3.91 (m, 1H, H-2), 3.79 (t, 1H, J2,3 = J3,4 = 5.7 
Hz, H-3), 3.45 (s, 3H, OMe), 3.05 (dd, 1H, J5,6b = 7.0 Hz, H-6b), 2.91 (dd, 1H, J6a.6b = 13.3 Hz, J5.6a 
= 4.9 Hz, H-6a), 1.35, 1.50 (2s, each 3H, CMe2). 13C NMR (CDCl3, 50 MHz): δ 109.5 (CMe2), 98.7 
(C-1), 76.4 (C-3), 74.0 (C-4), 69.3, 69.7 (C-5, C-2), 55.4 (OMe), 42.8 (C-6), 25.9, 27.8 (CMe2). 
Anal. for C10H19NO5. Calc. (%): C, 51.49; H, 7.95; N, 6.00. Found (%): C, 50.97; H, 8.25; N, 5.77.
4.2.6. Methyl-6-amino-6-deoxy-3,4-O-isopropylidene-β-D-galactopyranoside (16)
This compound was prepared starting from 14 (630 mg, 2.44 mmol) by a procedure analogous to 
that of  15. White solid 463 mg (81%); mp (hexane) 146-153 °C; optical rotation (c 1.0, CHCl3): 
[α]D -18.9. 1H NMR (CDCl3, 200 MHz): δ 4.11 (d, 1H, J = 8.3 Hz, H-1), 4.08 (m, 2H, H-3, H-4), 
3.73 (ddd, 1H, J4,5 = 1.9 Hz, H-5), 3.55 (s, 3H, OMe), 3.49 (t, 1H, J = 7.8 Hz, H-2), 3.14 (dd, 1H, 
J5.6’ = 7.6 Hz, H-6b), 2.96 (dd, 1H, J6,6’ = 13.3 Hz, J5,6 = 4.7 Hz H-6a), 2.48 (bs, 1H, OH), 1.50, 1.34 
(2s, each 3H, CMe2).  13C NMR (CDCl3, 50 MHz): δ 110.0 (CMe2), 103.4 (C-1), 79.3 (C-3), 74.4, 
74.1, 73.3 (C-2, C-5, C-4), 56.8 (OMe), 42.6 (C-6), 28.1, 26.2 CMe2). Anal. for C10H19NO5. Calc. 
(%): C, 51.49; H, 7.95; N, 6.00. Found (%): C, 50.93; H, 7.83; N, 5.85.
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4.3. General method for the parallel synthesis of amides of type 1, 3, 5 and 6
A 0.2 M solution of amine scaffold in CH2Cl2 and a 0.4 M solution of the selected acyl chloride in 
CH2Cl2 where prepared under anhydrous conditions.
In each reactor 1.00 g of resin PS-piperidinomethyl was put and in sequence 5 mL of the solution 
containing  the  amine  and 5  mL of  the  solution  containing  the  acyl  chloride  were  added.  The 
reaction mixture was stirred a room temperature for 12 hours. The reaction proceeding was checked 
by HPLC-MS. A 1.00 g of resin polyamine (loading = 3.2 mmol/g) to extract the excess the acyl 
chloride was added after dilution with CH2Cl2 (5 mL) and vortically stirred for two hours. The 
suspension  were  filtered  on  paper  and  the  clear  solutions  were  evaporated  under  diminished 
pressure to give oils that were purified by a Combi Flash chromatographic system (ISCO, using 
columns  Redisep  of  10  g  eluting  with  a  CH2Cl2-MeOH  gradient  from  98:2  to  95:5.  After 
evaporation of the solvent pure products were obtained.
4.4. General method of the synthesis of selectively deprotected furanosic amides of type 1 and 3
The  fully  protected  amides  of  type  1 and  3 (1.5-3.0  mmol),  prepared  following  the  general 
procedure  reported  above,  were  dissolved  in  80%  aqueous  AcOH  (20  mL)  and  the  resulting 
solutions were warmed to 60 °C in the case of hydrolysis of amides of type 1 and to 45 °C in the 
case of amides of type 3. Reaction mixtures were maintained under stirring until the TLC analysis 
(Hexane-EtOAc)  revealed  the  disappearance  of  starting  material  (1-4  h).  The  solution  were 
repeatedly coevaporated with toluene (5 × 10 mL) under diminished pressure. The crude residues 
were purified by a Combi Flash chromatographic system (ISCO, using columns Redisep of 10 g 
and as eluted a CH2Cl2-MeOH gradient from 98:5 to 90:10. After evaporation of the solvent pure 
products were obtained.
4.5. Active carbamides
4.5.1.  3-N-(2-Butynoyl)-3-deoxy-1,2:5,6-di-O-isopropylidene-α-D-glucofuranose  (1Ca).  From  7 
(778 mg, 3.00 mmol) by acylation with 2-butynoyl chloride. white solid 705 mg (72%);  Rf 0.32 
(hexane-EtOAc 3:7); mp (chrom) 160-162 °C; optical rotation (c 1.0, CHCl3): [α]D -47.3; 1H NMR 
(250 MHz, CD3CN): see Table 5 and δ 1.93 (s, 3H, MeC≡), 1.44, 1.36, 1.28, 1.26 (4s, each 3H, 2 × 
CMe2);  13C NMR (62.9 MHz, CD3CN): see Table 6 and  δ 153.7 (CO), 112.6, 110.0 (2  × CMe2), 
84.9 (≡CCO); 75.2 (MeC≡), 27.9, 27.8, 26.3, 25.4 (2 × CMe2), 3.5 (MeC≡); Anal. for C16H23NO6. 
Calc (%): C, 59.07; H, 7.13, N, 4.30. Found (%): C, 58.87; H, 7.16, N, 4.28.
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4.5.2.  3-N-Propanoyl-3-deoxy-1,2-O-isopropylidene-α-D-glucofuranose  (2Ab).  From  7 (778  mg, 
3.00 mmol) by acylation with propanoyl chloride and subsequent hydrolysis; colourless syrup 504 
mg (61%); Rf 0.27 (EtOAc-MeOH 9:1); optical rotation (c 1.0, MeOH): [α]D +15.4; 1H NMR (250 
MHz, CD3CN): see Table 3 and δ 2.30 (bs, 2H, OH-5, OH-6), 2.25 (t, 2H,  J = 7.5 Hz,  CH2CO), 
1.45, 1.27 (2s, each 3H, CMe2), 1.08 (t, 3H, J = 7.5 Hz, Me); 13C NMR (62.9 MHz, CD3CN): see 
Table 4 and δ 176.6 (CO), 112.4 (CMe2), 29.7 (CH2CO), 26.7, 26.3 (CMe2), 10.2 (Me). Anal. for 
C12H21NO6. Calc (%): C, 52.35; H, 7.69, N, 5.09. Found (%): C, 52.16; H, 7.72, N, 5.07.
4.5.3. 3-N-Butanoyl-3-deoxy-1,2-O-isopropylidene-α-D-glucofuranose (2Ac). From 7 (778 mg, 3.00 
mmol) by acylation with butanoyl  chloride and subsequent hydrolysis; colourless syrup 564 mg 
(65%);  Rf 0.43 (EtOAc-MeOH 9:1);  optical  rotation (c 1.0, MeOH): [α]D +19.8;  1H NMR (200 
MHz, CDCl3): see Table 3 and δ 3.60 (bs, 2H, OH-5, OH-6), 2.23 (t, 2H, J = 7.0 Hz, CH2CO), 1.58 
(m, 2H, CH2Me), 1.50, 1.30 (2s, each 3H, CMe2), 0.91 (t, 3H, J = 7.2 Hz, Me); 13C NMR (50 MHz, 
CDCl3):  see Table 4 and  δ 175.2 (CO),  111.7 (CMe2),  37.8 (CH2CO), 26.2,  25.8 (CMe2),  18.9 
(CH2Me), 13.5 (Me). Anal. for C13H23NO6. Calc (%): C, 53.97; H, 8.01, N, 4.84. Found (%): C, 
54.18; H, 8.04, N, 4.86.
4.5.4.  3-N-Pentanoyl-3-deoxy-1,2-O-isopropylidene-α-D-glucofuranose  (2Ad). From  7 (778  mg, 
3.00 mmol) by acylation with pentanoyl chloride and subsequent hydrolysis; colourless syrup 574 
mg (52%);  Rf 0.25 (EtOAc);  optical  rotation  (c 1.4,  MeOH): [α]D +25.7;  1H NMR (250 MHz, 
CD3CN):  see Table 3 and  δ 4.30,  2.38 (2bs,  each 1H, OH-5, OH-6),  2.20 (t,  2H,  J = 7.4 Hz, 
CH2CO), 1.55 (m, 2H, CH2CH2CO), 1.34 (m, 2H, CH2Me), 1.45, 1.27 (2s, each 3 H, CMe2), 0.90 (t, 
3H, J = 7.3 Hz, Me); 13C NMR (62.9 MHz, CD3CN): see Table 4 and δ 176.0 (CO), 112.5, (CMe2), 
36.3  (CH2CO),  28.6  (CH2CH2CO),  26.7,  26.4  (CMe2),  23.0  (CH2Me),  14.1  (Me).  Anal.  for 
C14H25NO6. Calc (%): C, 55.43; H, 8.31, N, 4.62. Found (%): C, 55.21; H, 8.34, N, 4.58.
4.5.5. 3-N-hexanoyl-3-deoxy-1,2-O-isopropylidene-α-D-glucofuranose (2Ae). From 7 (778 mg, 3.00 
mmol) by acylation with hexanoyl  chloride and subsequent hydrolysis; colourless syrup 628 mg 
(66%);  Rf 0.42 (EtOAc-MeOH 95:5);  optical rotation (c 1.0, MeOH): [α]D +23.2;  1H NMR (250 
MHz, CD3CN-D2O): see Table 3 and δ 2.18 (t, 2H, J = 6.4 Hz, CH2CO), 1.54 (m, 2H, CH2CH2CO), 
1.27 [(m, 4H, (CH2)2Me], 1.44, 1.26 (2s, each 3H, CMe2), 0.89 (t, 3H, J = 6.7 Hz, Me); 13C NMR 
(62.9  MHz,  CD3CN-D2O):  see  Table  6  and  δ 176.5 (CO),  112.7 (CMe2),  36.5  (CH2CO),  32.0 
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(CH2CH2CO), 26.6, 26.2 (CMe2), 26.1, 23.0 [(CH2)2Me],14.2 (Me). Anal. for C15H27NO6. Calc (%): 
C, 56.77; H, 8.57, N, 4.41. Found (%): C, 57.02; H, 8.61, N, 4.39.
4.5.6. 3-N-(3-Methylbutanoyl-3-deoxy-5,6-O-isopropylidene-α-D-glucofuranose (2Af). From 7 (778 
mg,  3.00 mmol)  by acylation with  3-methylbutanoyl chloride and subsequent  hydrolysis;  white 
solid 501 mg (55%);  Rf 0.28 (EtOAc);  mp (hexane) 115-116 °C; optical rotation (c 0.4, CHCl3): 
[α]D +46.3;  1H NMR (200 MHz, CD3CN): see Table 3 and  δ 4.23 (bs, 1H, OH-5), 2.77 (bt, 1H, 
OH-6), 2.06 (m, 2H, CH2CO), 2.02 (m, 1H, CHMe2), 1.45, 1.27 (2s, each 3H, CMe2), 0.92 (d, 6H, J 
= 6.2 Hz, 2 x Me); 13C NMR (50 MHz, CD3CN): see Table 4 and δ 175.2 (CO), 112.5, (CMe2), 45.7 
(CH2CO), 26.9 (CHMe2),  26.8, 26.3 (CMe2), 22.6 (2 x  Me).  Anal.  for C14H25NO6. Calc (%): C, 
55.43; H, 8.31, N, 4.62. Found (%): C, 55.30; H, 8.34, N, 4.60.
4.5.7. 3-N-(3,3-Dimethylbutanoyl)-3-deoxy-1,2-O-isopropylidene-α-D-glucofuranose (2Ah). From 7 
(778 mg, 3.00 mmol) by acylation with 3,3-dimethylbutanoyl chloride and subsequent hydrolysis; 
colourless syrup, 505 mg (53%); Rf 0.47 (EtOAc-MeOH 95:5); optical rotation (c 1.0, CHCl3): [α]D 
+35.4;  1H NMR (250 MHz, CD3CN): see Table 3 and δ 4.31, 2.85 (2bs, each 1H, OH-5, OH-6), 
2.08 (m, 2H, CH2CO), 1.45, 1.27 (2s, each 3H, CMe2), 1.01 (s, 9H, CMe3); 13C NMR (62.9 MHz, 
CD3CN): see Table 4 and δ 174.5 (CO), 112.5 (CMe2), 50.0 (CH2CO), 31.4 (CMe3), 30.1 (CMe3), 
26.8, 26.4 (CMe2). Anal. for C15H27NO6. Calc (%): C, 56.77; H, 8.57, N, 4.41. Found (%): C, 56.59; 
H, 8.55, N, 4.43.
4.5.8. 3-N-Pivaloyl-3-deoxy-1,2-O-isopropylidene-α-D-glucofuranose (2Aj). From 7 (778 mg, 3.00 
mmol) by acylation with  3,3-Dimethylbutanoyl chloride and subsequent hydrolysis;  white solid, 
821 mg (90%);  Rf 0.44 (EtOAc-MeOH 95:5);  mp (chrom)  161-163 °C; optical  rotation  (c 1.0, 
CHCl3): [α]D +22.3; Compound  2Aj 1H NMR (200 MHz, CDCl3): see Table 3 and  δ 4.35, 3.02 
(2bs, each 1H, OH-5, OH-6), 1.51, 1.31 (2s, each 3H, CMe2), 1.21 (s, 9H, CMe3);  13C NMR (50 
MHz, CDCl3): see Table 4 and δ 180.3 (CO), 111.9, (CMe2), 38.8 (CMe3), 27.4 (CMe3), 26.4, 26.2 
(CMe2). Anal. for C14H25NO6. Calc (%): C, 55.43; H, 8.31, N, 4.62. Found (%): C, 55.62; H, 8.35, 
N, 4.60.
4.5.9.  3-N-Propanoyl-3-deoxy-1,2:5,6-di-O-isopropylidene-α-D-allofuranose  (3Ab). From  8 (778 
mg, 3.00 mmol) by acylation with propanoyl chloride; white solid, 833 mg (88%); Rf 0.60 (EtOAc-
MeOH 9:1); mp (hexane) 93-95 °C; optical  rotation (c 1.0, CHCl3):  [α]D +71.1;  1H NMR (200 
MHz, CD3CN): see Table 5 and δ 2.15 (q, 2H, J = 7.5 Hz, CH2CO), 1.50, 1.34, 1.29, 1.27 (4s, each 
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3H, 2  × CMe2), 1.05 (t, 3H,  Me);  13C NMR (50 MHz, CD3CN): see Table 6 and  δ 174.3 (CO), 
112.9, 109.9 (2  × CMe2), 29.6 (CH2CO), 26.9, 26.6, 26.5, 25.4 (2  × CMe2), 10.1 (Me). Anal. for 
C15H25NO6. Calc (%): C, 57.13; H, 7.99, N, 4.44. Found (%): C, 57.39; H, 8.02, N, 4.42.
4.5.10.  3-N-Cyclopentanecarbonyl-3-deoxy-1,2:5,6-di-O-isopropylidene-α-D-allofuranose  (3An). 
From 8 (778 mg, 3.00 mmol) by acylation with cyclopentanecarbonyl chloride; white solid, 960 mg 
(90%); Rf 0.33 (hexane-EtOAc 1:1); mp (chrom) 102-104 °C; optical rotation (c 1.0, CHCl3): [α]D 
+65.5; 1H NMR (200 MHz, CD3CN): see Table 5 and δ 2.61 (m, 1H, CH), 1.63 (m, 8H, cyclopentyl 
H), 1.50, 1.34, 1.29, 1.26 (4s, each 3H, 2 × CMe2); 13C NMR (50 MHz, CD3CN): see Table 6 and δ 
176.8 (CO), 113.0, 110.0 (2 × CMe2), 45.8 (CH); 31.3, 30.7 (2 × CH2), 26.9, 26.7, 26.6, 25.6 (2 × 
CMe2), 26.7 (2 × CH2). Anal. for C18H29NO6. Calc (%): C, 60.83; H, 8.22, N, 3.94. Found (%): C, 
60.58; H, 8.25, N, 3.94.
4.5.11. 3-N-(3-Methoxyphenylacetyl)-3-deoxy-1,2:3,4-di-O-isopropylidene-α-D-allofuranose (3Bb). 
From 8 (778 mg, 3.00 mmol) by acylation with 3-methoxyphenylacetyl chloride; colourless syrup, 
1004 mg (82%); Rf 0.50 (EtOAc); optical rotation (c 1.0, CHCl3): [α]D +70.1; 1H NMR (250 MHz, 
CD3CN): see Table 5 and δ 7.23 (dd, 1H, J6’,5’ = 8.0 Hz, J4’,5’ = 8.2 Hz,  H-5’), 6.86 (m, 2H, H-2’, 
H-6’), 6.82 (ddd, 1H, J 2.5 Hz, J 1.0 Hz, H-4’), 3.77 (s, 3H, OMe), 3.47 (s, 2H, PhCH2), 1.48, 1.31, 
1.28, 1.25 (4s, each 3H, 2 × CMe2); 13C NMR (62.9 MHz, CD3CN): see Table 6 and δ 171.3 (CO), 
160.8 (C-3’), 138.3 (C-1’), 130.5 (C-5’), 122.4, 115.8, 113.1 (C-2’, C-4’, C-6’), 113.0, 110.0 (2 × 
CMe2), 55.8 (OMe), 43.4 (PhCH2), 26.7, 26.6, 26.5, 25.5 (2  × CMe2); Anal. for C21H29NO7. Calc 
(%): C, 61.90; H, 8.31, N, 3.44. Found (%): C, 61.87; H, 8.35, N, 3.43.
4.5.12.  3-N-(2,5-Dimethoxyphenylacetyl)-3-deoxy-1,2:3,4-di-O-isopropylidene-α-D-allofuranose 
(3Bd). From  8 (778  mg,  3.00  mmol)  by  acylation  with  2,5-dimethoxyphenylacetyl chloride; 
colourless syrup, 998 mg (76%); Rf 0.39 (hexane-EtOAc1:9); optical rotation (c 1.2, CHCl3): [α]D 
+57.1; 1H NMR (200 MHz, CD3CN): see Table 5 and δ  6.91-6.78 (m, 3H, H-3’, H-4’, H-6’), 3.78, 
3.72 (2s, each 3H, 2 × OMe), 3.44 (s, 2H, CH2CO), 1.47, 1.29, 1.28, 1.25 (4s, each 3H, 2 × CMe2); 
13C NMR (50 MHz, CD3CN): see Table  6 and  δ 171.4 (CO),  154.5,  152.4 (C-3’,  C-5’),  126.0 
(C-1’), 118.1, 113.4, 112.6 (C-3’, C-4’, C-6’), 113.0, 110.0 (2 × CMe2), 56.6, 56.2 (2 × OMe), 38.9 
(CH2CO), 26.8, 26.6, 26.5, 25.5 (2 × CMe2); Anal. for C22H31NO8. Calc (%): C, 60.40; H, 7.14, N, 
3.20. Found (%): C, 60.37; H, 7.14, N, 3.19.
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4.5.13.  3-N-Hydrocinnammoyl-3-deoxy-1,2:3,4-di-O-isopropylidene-α-D-allofuranose (3Bf). From 
8 (778 mg, 3.00 mmol) by acylation with  hydrocinnammoyl chloride; colourless syrup, 846 mg 
(72%);  Rf 0.72 (EtOAc-MeOH 9:1); optical rotation (c +1.0, CHCl3): [α]D +66.6;  1H NMR (200 
MHz, CD3CN): see Table 5 and δ  7.25 (m, 5H, Ar-H), 2.89, 2.47 (2t, each 2H, J 8.1 Hz, 2 × CH2), 
1.49, 1.34, 1.28, 1.28 (4s, each 3H, 2  × CMe2);  13C NMR (50 MHz, CD3CN): see Table 6 and  δ 
172.9 (CO), 142.3 (Ar-C), 129.3-127.0 (Ar-CH), 113.0, 110.0 (2  × CMe2), 38.2, 32.1 (2  × CH2), 
26.9, 26.6, 26.5, 25.5 (2 × CMe2); Anal. for C21H29NO6. Calc (%): C, 64.43; H, 7.47, N, 3.58. Found 
(%): C, 64.38; H, 7.50, N, 3.57.
4.5.14. 3-N-Butanoyl-3-deoxy-1,2-O-isopropylidene-α-D-allofuranose (4Ac). From 8 (778 mg, 3.00 
mmol) by acylation with butanoyl chloride and subsequent hydrolysis; white solid, 556 mg (64%); 
Rf 0.32 (EtOAc); mp (chrom) 123-124 °C; optical rotation (c 1.0, CHCl3): [α]D +4.4; 1H NMR (200 
MHz, CD3CN): see Table 3 and δ 3.76 (d, 1H, J5,OH = 4.6 Hz, OH-5), 2.80 (dd, 1H, J6a,OH = 5.4 Hz, 
J6b,OH = 6.5 Hz, OH-6), 2.17 (t, 2H, J = 7.2 Hz, CH2CO), 1.53 (sestetto, 2H, CH2Me); 1.50, 1.30 (2s, 
each 3H, CMe2), 0.90 (t, 3H, J = 7.4 Hz, Me); 13C NMR (50 MHz, CD3CN): see Table 4 and δ 175.0 
(CO),  113.0  (CMe2),  38.5  (CH2CO),  26.9,  26.7,  (CMe2),  19.7  (CH2Me),  13.9  (Me);  Anal.  for 
C13H23NO6. Calc (%): C, 55.97; H, 8.01, N, 4.84. Found (%): C, 55.88; H, 8.04, N, 4.86.
4.5.15.  3-N-(2-Methylpropanoyl)-3-deoxy-1,2-O-isopropylidene-α-D-allofuranose  (4Ai). From  8 
(778 mg, 3.00 mmol) by acylation with  2-methylpropanoyl chloride and subsequent hydrolysis; 
white solid, 460 mg (53%); Rf 0.26 (EtOAc-MeOH 95:5); mp (chrom) 105-107 °C; optical rotation 
(c 1.0, CHCl3): [α]D +4.6; 1H NMR (250 MHz, CD3CN): see Table 3 and δ 3.73 (d, 1H, J5,OH = 4.8 
Hz, OH-5), 2.84 (dd, 1H, J6a,OH = 5.3 Hz, J6b,OH = 6.6 Hz, OH-6), 2.45 (ept, 1H, J = 6.8 Hz, CHMe2), 
1.51, 1.30 (2 s, each 3H, CMe2), 1.06, 1.07 (2d, each 3H, J = 6.8 Hz, CHMe2); 13C NMR (62.9 MHz, 
CD3CN): see Table 4 and  δ 178.8 (CO), 113.0 (CMe2), 35.6 (CHMe2),  26.9, 26.7 (CMe2), 19.7 
(CHMe2). Anal. for C13H23NO6. Calc (%): C, 53.97; H, 8.01, N, 4.84. Found (%): C, 53.99; H, 7.99, 
N, 4.82.
4.5.17. 3-N-Pivaloyl-3-deoxy-1,2-O-isopropylidene-α-D-allofuranose (4Aj). From 8 (778 mg, 3.00 
mmol) by acylation with pivaloyl chloride and subsequent hydrolysis; white solid, 510 mg (56%); 
Rf 0.36 (EtOAc-MeOH 95:5); mp (chrom) 107-108 °C; optical rotation (c 1.0, CHCl3): [α]D +8.5; 
1H NMR (200 MHz, CD3CN): see Table 3 and δ 3.58 (bs, 1H, OH-5), 2.76 (bt, 1H, OH-6), 1.51, 
1.31 (2s, each 3H, CMe2), 1.16 (s, 9H,  CMe3);  13C NMR (50 MHz, CD3CN): see Table 4 and  δ 
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172.6 (CO), 113.0, (CMe2), 39.4 (CMe3), 27.5 (CMe3), 26.8, 26.7, (CMe2). Anal. for C14H25NO6. 
Calc (%): C, 55.43; H, 8.31, N, 4.62. Found (%): C, 55.47; H, 8.32, N, 4.64.
4.5.16.  3-N-(Biphenyl-4-carbonyl)-3-deoxy-1,2-O-isopropylidene-α-D-allofuranose (4Bh). From  8 
(778 mg, 3.00 mmol) by acylation with  biphenyl-4-carbonyl chloride and subsequent hydrolysis; 
white solid, 685 mg (57%); Rf 0.29 (EtOAc); mp (chrom) 176-178 °C; optical rotation (c 1, CHCl3): 
[α]D +107.0; 1H NMR (250 MHz, CD3CN): see Table 3 and δ 7.94 (m, 2H, Ar-H), 7.71 (m, 4H, Ar-
H), 7.45 (m, 3H, Ar-H), 3.65 (d, 1H, J5,OH = 4.7 Hz, OH-5), 2.88 (dd, 1H, J6a,OH = 5.7 Hz, J6b,OH = 6.3 
Hz, OH-6), 1.55, 1.33 (2s, each 3H, CMe2); 13C NMR (62.9 MHz, CD3CN): see Table 4 and δ 168.8 
(CO), 145.1, 140.7, 133.7 (3  × Ar-C), 130.0-128.0 (Ar-CH), 113.1, (CMe2), 27.0, 26.7, (CMe2). 
Anal. for C22H25NO6. Calc (%): C, 66.15; H, 6.31, N, 3.51. Found (%): C, 66.17; H, 6.32, N, 3.50.
4.5.18.  3-N-(4-Methoxybenzoyl)-3-deoxy-1,2-O-isopropylidene-α-D-allofuranose  (4Bi). From  8 
(778 mg,  3.00 mmol)  by acylation  with  4-methoxybenzoyl chloride and subsequent hydrolysis; 
white solid, 583 mg (55%); Rf 0.35 (EtOAc-MeOH 9:1); mp (chrom) 180-182 °C; optical rotation 
(c 1.0, CHCl3): [α]D +26.7; 1H NMR (250 MHz, CD3CN-D2O): see Table 3 and δ 7.70 (AA’XX’, 
2H, H-2’,  H-6’),  6.97 (AA’XX’, 2H, H3’,  H-5’),  3.81 (s,  3H,  OMe),  1.51,  1.28 (2s,  each 3H, 
CMe2); 13C NMR (62.9 MHz, CD3CN): see Table 4 and δ 168.7 (CO), 163.5 (C-4’), 126.8 (C-1’), 
130.3 (C-2’, C-6’), 114.8 (C-3’, C-5’), 113.3 (CMe2), 56.2 (OMe), 26.9, 26.6, (CMe2). Anal. for 
C17H23NO7. Calc (%): C, 57.78; H, 6.56, N, 3.96. Found (%): C, 67.72; H, 6.59, N, 3.95.
4.5.19. Methyl-6-N-butanoyl-6-deoxy-3,4-O-isopropylidene-α-D-galactopyranoside (5Ac). From 15 
(700 mg, 3.00 mmol) by acylation with butanoyl chloride; colourless syrup, 737 mg (81% ); Rf 0.30 
(EtOAc-MeOH 95:5); optical rotation (c 1.0, CHCl3): [α]D +111.0;  1H NMR (250 MHz, CD3CN-
D2O): see Table 5 and δ 3.32 (s, 3H, OMe), 2.70 (bs, 1H, OH), 2.10 (t, 2H, J = 7.2 Hz, CH2CO), 
2.02 (m, 2H, CH2CH2CO), 1.43, 1.29 (2s, each 3H, CMe2), 0.89 (t, 3H, J = 7.4 Hz, Me); 13C NMR 
(62.9 MHz, CD3CN): see Table 4 and  δ 173.9 (CO), 109.8 (CMe2), 55.7 (OMe), 38.7 (CH2CO), 
28.3, 26.5 (CMe2), 19.9 (CH2CH2CO), 14.0 (Me). Anal. for C10H19NO5. Calc (%): C, 51.49; H, 8.21, 
N, 6.00. Found (%): C, 51.50; H, 8.23, N, 5.58.
4.5.20.  Methyl-6-N-cyclopropanecarbonyl-6-deoxy-3,4-O-isopropylidene-β-D-galctopyranoside 
(6Al). From 16 (700 mg, 3.00 mmol) by acylation with cyclopropanecarbonyl chloride; white solid, 
679 mg (75%); Rf 0.40 (EtOAc-MeOH 9:1); mp (chrom) 65-67 °C; optical rotation (c 1.1, CHCl3): 
[α]D +37.2; 1H NMR (200 MHz, CD3CN-D2O): see Table 5 and δ 3.47 (s, 3H, OMe), 3.28 (bs, 1H, 
16
OH), 1.48 (m, 1, CH), 1.43, 1.30 (2s, each 3H, CMe2), 0.85-0.66 (m, 4H, CH2CH2); 13C NMR (50 
MHz, CD3CN): see Table 4 and δ 174.6 (CO), 110.3 (CMe2), 56.9 (OMe), 28.4, 26.6 (CMe2), 14.6 
(CH), 7.1 (CH2CH2). Anal. for C14H25NO6. Calc (%): C, 55.43; H, 8.31, N, 4.62.  Found (%): C, 
55.45; H, 8.33, N, 4.62.
Acknowledgements
R.G. is granted by Associazione Italiana Ricerca sul Cancro (AIRC), Fondazione Cariparo (Cassa di 
Risparmio di Padova e Rovigo), Associazione Veneta per la Lotta alla Talassemia – Rovigo, Italy 
(AVLT), Telethon (grant GGP07257) and STAMINA Project. We thank the EU Project ITHANET 
(eInfrasctructure  for  Thalassemia  Research  Network)  for  support.  M.L.  was  supported  by  a 
fellowship from AVLT and from“Associazione per la Lotta alla Talassemia di Ferrara – Ferrara, 
Italy”. Partial support from Universities of Pisa and Ferrara is also acknowledged.
17
References
1. Lozzio, B.B; Lozzio, C.B. Blood 1975, 45, 321-334.
2. (a) Lampronti, I.; Bianchi, N.; Borgatti, M.; Fibach, E.; Prus, E.; Gambari, R. Eur. J. Haematol. 
2001, 71, 189-195; (b) Gambari, R. Minerva Biotecnol. 2003, 15, 123–128.
3. (a) Fibach, E.; Bianchi, N.; Borgatti, M.; Prus, E.; Gambari, R. Blood 2003, 102, 1276-1281; (b) 
Zuccato, C.; Bianchi, N.; Borgatti, M.; Lampronti, I.; Massei, F.; Favre, C.; Gambari, R. Acta  
Haematol.  2007,  117, 168-176; (c) Fibach, E.; Bianchi, N.; Borgatti, M.; Zuccato, C.; Finotti, 
A.; Lampronti, I.; Prus, E.; Mischiati, C.; Gambari, R. Eur. J. Haematol. 2006, 77, 437-441; (d) 
Gambari, R.; Fibach, E. Curr. Med. Chem. 2007, 14, 199-212.
4. Jeannesson, P.; Lahlil, R.; Chenais, B.; Devy, L.; Gillet, R.; Aries, A.; Morceau, F.; Trentesaux, 
C. Leuk. Lymphoma 1997, 26, 575-587.
5. Bianchi,  N.;  Osti,  F.;  Rutigliano,  C.;  Ginanni  Corradini,  F.;  Bosetti,  E.;  Tommasetti,  M.; 
Mischiati, C.; Feriotto, G.; Gambari, R.; Br. J. Haematol. 1999, 104, 258-265.
6. Bianchi, N.; Ongaro, F.; Chiarabelli, C.; Gualandi, L.; Mischiati, C.; Bergamini, P.; Gambari, R. 
Biochemical Pharm. 2000, 60, 31-40.
7. Bianchi,  N.;  Chiarabelli,  C.;  Borgatti,  M.;  Mischiati,  C.;  Fibach,  E.;  Gambari,  R.  Br.  J.  
Haematol. 2001, 113, 951-961.
8. Pouillart, P.; Ronco, G.; Cerutti, I.; Trouvin, J.H.; Pieri, F.; Villa, P.  J. Pharm. Sci. 1992,  81, 
241-244.
9. (a) Catelani, G.; Osti, F.; Bianchi, N.; Bergonzi, M.C.; D’Andrea, F.; Gambari, R. Bioorg. Med.  
Chem. Lett.  1999,  9, 3153-3158; (b) Bergonzi, M.C.; Bianchi, N.; Catelani, G.; D’Andrea, F.; 
Gambari, R.; Lipucci di Paola, M.; Osti, F. Eur. Patent 1004590 A2, 2000, Chem. Abstr. 2000, 
133, 4898; (c) Catelani, G.; D’Andrea, F.; Mastrorilli, E.; Bianchi, N.; Chiarabelli, C.; Borgatti, 
M.;  Martello,  D.;  Gambari,  R.  Bioorg.  Med.  Chem. 2002,  10,  347-353;  (d)  Catelani,  G.; 
D’Andrea,  Landi,  M.;  Zuccato,  C.;  Bianchi,  N.;  Gambari,  R.  Carbohydr.  Res. 2006,  341, 
538-544.
10. Unpublished results from Chiesi Laboratories.
11. Kunz, H.; P. Schmidt, Liebigs Ann. Chem. 1982, 1245-1260.
12. (a)  Baer,  H.;  Gan,  Y.  Carbohyd.  Res. 1991,  210,  233-245;  (b)  Fernandez,  J.;  Mellet,  C.; 
Jimenez, J.; Fuentes, J., J. Org. Chem. 1994, 59, 5565-5572.
13. Catelani, G.; Colonna, F.; Marra, A. Carbohydr. Res. 1988, 182, 297-300.
14. Wolfrom, M.L.; Shafizadeh, F.; Armstrong, R.K.; Shen Han, T.M. J. Am. Chem. Soc. 1959, 81, 
3716-3718.
15. Brimacombe, J.S.; Ching, O.A. J. Chem. Soc. (C) 1968, 1642-1646.
18
16. Collins, P.M. Tetrahedron 1965, 21, 1809-1815.
17. Lozzio, B.B.; Lozzio, C.B. Int. J. Cancer 1977, 19, 136.
18. Gambari, R.; Del Senno, L.; Barbieri, R.; Vola, L.; Tripodi, M.; Raschella, G.; Fantoni, A. Cell  
Differentiation 1984, 14, 87-97. 
19. Watanabe,  T.;  Mitchell,  T.;  Sariban,  E.;  Sabbath,  K.;  Griffin,  J.;  Kufe,  D.  Mol.  Pharmacol. 
1985, 27, 683-688.
20. (a) Fibach,  E.; Burke,  L.P.; Schechter,  A.N.;  Noguchi,  C.T.;  Rodgers, G.P.  Blood 1993,  81, 
1630-1635; (b) Fibach, E.; Prasanna, P.; Rodgers, G.P.; Samid, D. Blood 1993, 82, 2203-2209.
21. Bock, K.; Pedersen, C. Adv. Carbohydr. Chem. Biochem. 1983, 41, 27-66.
22. Perrin, D.D; Armarengo, W.L.F.; Perrin, D.R.  Purification of Laboratory Chemicals; 2nd ed; 
Pergamon Press: Oxford, 1980.
23. Manganiello,  F.J.;  Christensen,  L.W.;  Jones,  W.M.  J  Organometallic  Chem. 1982,  235, 
327-334.
24. Rao, P.A.; Smith, F. J. Chem. Soc. 1944, 229-232.
19
Table 3: 1H NMR data (δ, ppm; J, Hz) for compounds of type 2 and 4
Compound Solvent H-1 H-2 H-3 H-4 H-5 H-6a H-6b NH J1,2 J2,3 J3,4 J3,NH J4,5 J5,6a J5,6b J6a,6b
2Ab CD3CN 5.84 4.59 4.20 4.01 3.50 3.50 3.64 6.87 3.7 0 3.2 7.6 8.4 n.d. 2.2 10.4
2Ac CDCl3 5.89 4.58 4.36 4.10 3.70 3.70 3.70 7.49 3.7 0 3.2 7.1 7.3 n.d. n.d. n.d.
2Ad CD3CN 5.83 4.50 4.21 4.01 3.49 3.49 3.66 6.96 3.7 0 3.2 7.7 8.3 n.d. n.d. n.d.
2Ae CD3CN-D2O 5.83 4.49 4.21 4.02 3.55 3.55 3.62 -- 3.6 0 3.2 -- 7.9 n.d. 2.7 10.7
2Af CD3CN 5.83 4.50 4.20 4.00 3.53 3.53 3.53 6.84 3.6 0 3.1 7.8 8.2 n.d. n.d. n.d.
2Ah CD3CN 5.84 4.50 4.21 4.02 3.48 3.48 3.64 6.90 3.7 0 3.2 7.4 8.3 n.d. 2.6 10.3
2Aj CDCl3 5.89 4.56 4.31 4.15 3.90 3.70 3.70 6.84 3.7 0 3.4 6.4 6.4 n.d. n.d. n.d.
4Ac CD3CN 5.76 4.59 4.23 3.77 3.65 3.42 3.51 6.62 3.8 5.1 9.2 8.9 4.8 6.6 4.0 11.3
4Ai CD3CN 5.76 4.59 4.23 3.80 3.66 3.40 3.51 6.56 3.8 5.1 9.2 9.0 4.6 6.7 3.8 11.5
4Aj CD3CN 5.79 4.62 4.17 3.82 3.66 3.40 3.52 6.46 3.8 5.3 9.2 8.2 4.9 6.7 4.0 11.2
4Bh CD3CN 5.84 4.76 4.47 4.04 3.79 3.48 3.58 7.15 3.8 5.0 9.4 8.1 4.7 6.6 4.2 11.4
4Bi CD3CN-D2O 5.81 4.72 4.45 4.08 3.80 3.44 3.55 -- 3.8 4.9 9.7 -- 4.1 7.1 4.2 11.5
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Table 4: 13C NMR data (δ, ppm) for compounds of type 2 and 4
Compound Solvent C-1 C-2 C-3 C-4 C-5 C-6
2Ab CD3CN 105.6 84.8 57.0 79.8 70.0 64.4
2Ac CDCl3 104.2 83.7 56.3 78.5 69.4 63.7
2Ad CD3CN 105.5 84.8 57.1 79.8 70.1 64.4
2Ae CD3CN-D2O 105.5 84.8 56.7 79.4 70.0 64.1
2Af CD3CN 105.6 84.8 57.1 79.9 70.2 64.5
2Ah CD3CN 105.6 84.8 57.1 79.7 70.2 64.4
2Aj CDCl3 104.0 84.1 56.7 78.1 69.9 63.5
4Ac CD3CN 105.1 80.6 53.3 80.5 73.2 63.8
4Ai CD3CN 105.2 80.7 53.3 80.5 73.1 63.8
4Aj CD3CN 105.2 80.9 53.6 80.3 73.1 63.8
4Bh CD3CN 105.3 80.4 54.1 80.2 73.1 63.8
4Bi CD3CN-D2O 105.2 80.3 53.5 79.6 72.7 63.4
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Table 5. 1H NMR data (δ, ppm; J, Hz) for compounds of type 1, 3, 5 and 6
Compound Solvent H-1 H-2 H-3 H-4 H-5 H-6a H-6b NH J1,2 J2,3 J3,4 J3,NH J4,5 J5,6a J5,6b J6a,6b
1Ca CD3CN 5.81 4.46 4.33 4.10 4.20 3.83 4.05 7.05 3.7 0 3.7 8.8 7.2 5.5 6.1 8.4
3Ab CD3CN 5.75 4.55 4.13 3.90 4.13 3.90 3.90 6.43 3.7 4.3 n.d. 8.1 n.d. n.d. n.d. n.d.
3An CD3CN 5.75 4.54 4.19 3.91 4.11 3.91 3.91 6.43 3.6 4.3 9.5 8.8 n.d. n.d. n.d. n.d.
3Bd CD3CN 5.75 4.53 4.09 3.84 4.12 3.79 3.94 6.60 3.8 4.6 9.3 8.4 3.5 6.8 6.6 8.0
3Bf CD3CN 5.75 4.52 4.10 3.86 4.07 3.82 3.95 6.48 3.8 4.7 9.9 8.8 3.4 6.3 6.6 7.9
3Bb CD3CN 5.75 4.56 4.13 3.87 4.11 3.81 3.96 6.59 3.8 4.9 9.8 8.4 4.0 6.6 6.6 8.2
5Ac CD3CN 4.59 3.57 4.02 4.15 3.96 3.23 3.48 6.62 3.6 7.5 5.5 -- 2.4 7.8 4.4 13.7
6Al CD3CN 4.02 3.28 3.94 4.10 3.80 3.28 3.53 6.90 8.2 7.0 5.5 -- 2.1 8.4 4.2 13.8
22
Table 6: 13C NMR data (δ, ppm) for compounds of type 1, 3, 5 and 6
Compound Solvent C-1 C-2 C-3 C-4 C-5 C-6
1Ca CD3CN 105.6 85.2 56.4 79.5 73.7 67.5
3Ab CD3CN 105.3 80.1 53.6 78.9 76.4 65.4
3An CD3CN 105.3 80.1 53.7 79.0 76.5 65.6
3Bd CD3CN 105.3 80.0 53.5 79.2 76.3 65.2
3Bf CD3CN 105.4 80.0 53.7 78.8 76.3 65.3
3Bb CD3CN 105.4 80.0 54.0 79.1 76.5 65.6
5Ac CD3CN 100.4 70.8 77.4 74.7 66.8 40.7
6Al CD3CN 104.4 74.2 80.3 75.1 72.1 41.1
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